Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering.

盐湖城，2024年6月26日（环球通讯社）--Recursion Pharmaceuticals，Inc.（“Recursion”）（纳斯达克：RXRX），一家领先的临床阶段TechBio公司，解码生物学以使药物发现产业化，今天宣布，它打算在承销的公开发行中发行并出售2亿美元的a类普通股。

All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock offered. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

A类普通股的所有股份都是通过递归发行的。此外，Recursion打算授予承销商30天的期权，以购买所发行的a类普通股的另外15%的股份。拟议的发售受市场和其他条件的限制，并且无法保证发售是否或何时完成，也无法保证发售的实际规模或条款。

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. The shares will be offered by Recursion pursuant to a registration statement on Form S-3, which became automatically effective upon filing with the U.S.

高盛公司（Goldman Sachs&Co.LLC）和摩根大通（J.P.Morgan）担任此次发行的主要账簿管理人。艾伦公司（Allen&Company LLC）担任此次发行的账簿管理人。股票将根据S-3表格上的登记声明以递归方式发行，该登记声明在向美国提交后自动生效。

Securities and Exchange Commission (“SEC”) on May 10, 2022. The offering is being made solely by means of a written prospectus and a prospectus supplement that form a part of the registration statement. A copy of the preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

证券交易委员会（“SEC”）于2022年5月10日发布。本次发行仅通过书面招股说明书和招股说明书补充资料进行，招股说明书补充资料构成注册声明的一部分。与本次发行相关的初步补充招股说明书和随附招股说明书的副本将提交给美国证券交易委员会，并可在美国证券交易委员会的网站www.SEC.gov上查阅。

Alternatively, a copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus.

或者，也可以通过以下方式获得与本次发行相关的初步补充招股说明书和随附招股说明书的副本：高盛公司，收件人：招股说明书部，200 West Street，New York，NY 10282，电话：（866）471-2526或发邮件至招股说明书。